Truist Financial Corp

Truist’s latest equity and lending moves—buying PSA, Viking Therapeutics, and funding Repay Holdings’ KUBRA deal—show a balanced, data‑driven strategy for navigating real‑estate, fintech, and regulatory shifts.

Truist Financial’s latest regulatory updates, executive ownership tweaks, and high‑speed silicon photonics partnership reveal how banks balance capital reforms and tech innovation to stay competitive.

Truist’s latest equity research uncovers hidden risks and growth levers across banks, REITs, tourism, biotech and consumer goods, offering investors sharper insights for smarter portfolio decisions.

Truist Financial Corp. trades at $49.66, a mid‑range P/E of 13.12, offering defensive value amid stable earnings, strong capital ratios, and growth prospects in digital banking, green financing, and RegTech.

Truist Financial’s latest disclosure shows how its robust retail, commercial, and asset‑management core plus disciplined equity‑research drives resilient growth and sharp valuation insights, positioning it to navigate market dynamics and seize new o…

Truist’s Q4 2025 earnings fell short of expectations, but a $6 B share‑repurchase plan, strong capital base, and 2027 ROTE target signal confidence. Explore the bank’s cost pressures, regulatory landscape, fintech competition, and digital growth opp…

Truist raises price targets for Landstar and J.B. Hunt, citing modest revenue upside and supply‑chain demand, while noting a potential slowdown in housing‑construction.

Truist Financial’s Q4 earnings release, set for later this week, will gauge its health amid regulatory shifts, mortgage scrutiny, and a digital‑banking push.

Truist Financial’s updated income statement format boosts transparency and clarity, helping investors compare core earnings with peers and strengthen its competitive stance.

Truist Financial’s January equity coverage spotlights Palantir and generative‑AI stocks, emphasizing tech’s growth, data‑analytics power, and inflation‑resilient returns.